Molnupiravir
Treatment for Covid 19
Typical Dosage: 800 mg orally twice daily
Effectiveness
65%
Safety Score
65%
Clinical Trials
22
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
800 mg orally twice daily
Time to Effect
Within 5 days of symptom onset
Treatment Duration
5 days
Evidence Quality
MODERATENumber Needed to Treat (NNT)
45(Treat 45 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$700
Monitoring:$20
Side Effect Mgmt:$10
Total Annual:$730
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$140,000/QALY
QALYs Gained
0.008
Outcome-Based Costs
Cost per Responder
$2,085.71
Comparison vs No treatment / Supportive care
Cost Difference
+$600/year
More expensive
QALY Difference
+0.01 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
5 active trials recruiting for Molnupiravir in Covid 19
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700RECRUITINGPHASE3
3.08K participants
INTERVENTIONAL
Cullman, United States +223 more
Started: Dec 2, 2024
AGILE (Early Phase Platform Trial for COVID-19)
NCT04746183RECRUITINGPHASE1, PHASE2
600 participants
INTERVENTIONAL
Cape Town, South Africa +6 more
Started: Jul 3, 2020
COVID-19 International Drug Pregnancy Registry
NCT05013632RECRUITING
2K participants
OBSERVATIONAL
Los Angeles, United States
Started: Dec 1, 2021
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
NCT06160128RECRUITING
400K participants
OBSERVATIONAL
Portland, United States
Started: Sep 26, 2022
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
NCT05041907RECRUITINGPHASE2
3.8K participants
INTERVENTIONAL
Minas Gerais, Brazil +6 more
Started: Sep 30, 2021
Completed Clinical Trials
10 completed trials for Molnupiravir in Covid 19
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
NCT04405570COMPLETEDPHASE2
204 participants
INTERVENTIONAL
Northridge, United States +9 more
Started: Jun 19, 2020
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
NCT07720596COMPLETED
1.8M participants
OBSERVATIONAL
Prague, Czechia
Started: Jan 1, 2022
Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers
NCT05412173COMPLETEDNA
37 participants
INTERVENTIONAL
Saint Petersburg, Russia
Started: Apr 22, 2022
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
NCT04939428COMPLETEDPHASE3
2.44K participants
INTERVENTIONAL
Birmingham, United States +225 more
Started: Aug 11, 2021
Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)
NCT04575597COMPLETEDPHASE2, PHASE3
1.74K participants
INTERVENTIONAL
Peoria, United States +172 more
Started: Oct 19, 2020
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
NCT05459532COMPLETEDPHASE2, PHASE3
59 participants
INTERVENTIONAL
Umtata, South Africa +3 more
Started: Aug 12, 2022
Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19
NCT05595824COMPLETEDPHASE3
240 participants
INTERVENTIONAL
Ivanovo, Russia +11 more
Started: Dec 1, 2021
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
NCT05195060COMPLETED
1.18K participants
OBSERVATIONAL
Amsterdam, Netherlands +3 more
Started: Dec 14, 2021
COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
NCT04392219COMPLETEDPHASE1
130 participants
INTERVENTIONAL
Leeds, United Kingdom
Started: Apr 10, 2020
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
NCT05648799COMPLETEDNA
246 participants
INTERVENTIONAL
Kaliningrad, Russia +4 more
Started: Mar 17, 2022
Showing 20 of 23 total trials